DE69918283D1 - Stabilisierte herpesvirusformulierung - Google Patents

Stabilisierte herpesvirusformulierung

Info

Publication number
DE69918283D1
DE69918283D1 DE69918283T DE69918283T DE69918283D1 DE 69918283 D1 DE69918283 D1 DE 69918283D1 DE 69918283 T DE69918283 T DE 69918283T DE 69918283 T DE69918283 T DE 69918283T DE 69918283 D1 DE69918283 D1 DE 69918283D1
Authority
DE
Germany
Prior art keywords
herpesvirus
stabilized
virus
formulation
aminoacids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69918283T
Other languages
English (en)
Other versions
DE69918283T2 (de
Inventor
Alison Varley
Thomas Loudon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cantab Pharmaceuticals Research Ltd
Original Assignee
Cantab Pharmaceuticals Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantab Pharmaceuticals Research Ltd filed Critical Cantab Pharmaceuticals Research Ltd
Publication of DE69918283D1 publication Critical patent/DE69918283D1/de
Application granted granted Critical
Publication of DE69918283T2 publication Critical patent/DE69918283T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE1999618283 1998-04-24 1999-04-26 Stabilisierte herpesvirusformulierung Expired - Fee Related DE69918283T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9808922A GB9808922D0 (en) 1998-04-24 1998-04-24 Virus preparations
GB9808922 1998-04-24
PCT/GB1999/001295 WO1999055348A2 (en) 1998-04-24 1999-04-26 Stabilised virus preparation

Publications (2)

Publication Number Publication Date
DE69918283D1 true DE69918283D1 (de) 2004-07-29
DE69918283T2 DE69918283T2 (de) 2005-07-21

Family

ID=10831020

Family Applications (1)

Application Number Title Priority Date Filing Date
DE1999618283 Expired - Fee Related DE69918283T2 (de) 1998-04-24 1999-04-26 Stabilisierte herpesvirusformulierung

Country Status (12)

Country Link
US (1) US6258362B1 (de)
EP (1) EP1071438B1 (de)
JP (1) JP2002512970A (de)
AT (1) ATE269712T1 (de)
AU (1) AU3718299A (de)
CA (1) CA2329000C (de)
DE (1) DE69918283T2 (de)
DK (1) DK1071438T3 (de)
ES (1) ES2224646T3 (de)
GB (1) GB9808922D0 (de)
PT (1) PT1071438E (de)
WO (1) WO1999055348A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
US20040022800A1 (en) * 2000-07-31 2004-02-05 Mark Parrington Respiratory syncytial virus vaccine
US7101693B2 (en) 2001-09-07 2006-09-05 Brigham Young University Plasticized hydrophilic glasses for improved stabilization of biological agents
CA2467365C (en) * 2001-12-10 2012-11-20 Bavarian Nordic A/S Poxvirus containing formulations and process for preparing stable, poxvirus containing compositions
AU2008201215B2 (en) * 2001-12-10 2010-11-18 Bavarian Nordic A/S Poxvirus containing formulations and process for preparing stable, poxvirus containing compositions
ITMI20021040A1 (it) * 2002-05-16 2003-11-17 Novuspharma Spa Composizioni farmaceutiche iniettabili di un derivato antracenedionico ad attivita' antitumorale
US7592171B2 (en) * 2003-02-20 2009-09-22 Centro Nacional De Investigaciones Cientificas (Cnic) Vibrio cholerae with improved biological safety features in freeze dried form
EP1708747A2 (de) * 2004-01-15 2006-10-11 Intervet International BV Stabilisatoren nichttierischen ursprungs und herstellungsverfahren dafür
CA2571261C (en) * 2004-06-29 2018-08-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Safer attenuated virus vaccines with missing or diminished latency of infection
KR101400379B1 (ko) * 2004-11-05 2014-05-28 웰스테트 바이올로직스 코포레이션 안정하고 여과 가능한 외피보유 바이러스 조성물
US20060141483A1 (en) * 2004-12-23 2006-06-29 Calton Gary J Stabilization of viral compositions
US20070031450A1 (en) * 2005-08-04 2007-02-08 Wyeth Stabilizers for veterinary vaccines
WO2007079147A2 (en) 2005-12-28 2007-07-12 Advanced Bionutrition Corporation A delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
WO2008079539A2 (en) 2006-11-09 2008-07-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant herpesvirus with diminished latency and methods of using same
EP2117354B1 (de) 2006-12-18 2018-08-08 Advanced BioNutrition Corp. Trockenes nahrungsmittel mit lebendem probiotikum
US20080294361A1 (en) * 2007-05-24 2008-11-27 Popp Shane M Intelligent execution system for the monitoring and execution of vaccine manufacturing
US20110262943A1 (en) * 2008-10-17 2011-10-27 Tokyo University Of Marine Science And Technology Reagent kit for measuring freshness
WO2010111565A2 (en) 2009-03-27 2010-09-30 Advanced Bionutrition Corporation Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
EP2435554B1 (de) 2009-05-26 2017-07-26 Advanced Bionutrition Corporation Stabile trockenpulverzusammensetzung mit biologisch aktiven mikroorganismen und/oder bioaktiven materialien sowie herstellungsverfahren dafür
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
PL2529004T3 (pl) 2010-01-28 2017-12-29 Advanced Bionutrition Corporation Sucha szklista kompozycja zawierająca bioaktywny materiał
AR082682A1 (es) 2010-08-13 2012-12-26 Advanced Bionutrition Corp Composicion estabilizadora de almacenamiento en seco para materiales biologicos
CN101972474B (zh) * 2010-11-11 2012-06-27 长春祈健生物制品有限公司 冻干带状疱疹减毒活疫苗及制备方法
EP2646051A4 (de) 2010-12-02 2014-05-28 Oncolytics Biotech Inc Flüssige virale formulierungen
MX349294B (es) 2010-12-02 2017-07-21 Oncolytics Biotech Inc Formulaciones virales liofilizadas.
EP3246400B1 (de) 2012-01-09 2019-10-23 Sanofi Pasteur Biologics, LLC Aufreinigung von herpesvirus
EP2852662B1 (de) * 2012-05-21 2020-09-16 Sanofi Pasteur Limited Herpesviruszusammensetzungen und zugehörige verfahren
FR3024780B1 (fr) * 2014-08-07 2018-11-30 Bertin Pharma Reactif pret a l'emploi
US12558395B2 (en) 2015-07-29 2026-02-24 Advanced Bionutrition Corp. Stable dry probiotic compositions for special dietary uses
MY194231A (en) 2015-07-29 2022-11-23 Advanced Bionutrition Corp Stable dry probiotic compositions for special dietary uses
GB201701239D0 (en) * 2017-01-25 2017-03-08 Glaxosmithkline Biologicals Sa Novel formulation
US20220193222A1 (en) * 2018-11-30 2022-06-23 Vaccine Stabilization Institute Viral formulations containing amino acids
MX2021007639A (es) 2018-12-27 2021-08-11 Amgen Inc Formulaciones de virus liofilizadas.
CN116270500B (zh) * 2021-12-30 2025-05-06 安徽贝金基因科技有限公司 一种高稳定性的溶瘤病毒组合物及其制备方法和其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE209738C (de)
GB960850A (en) * 1961-09-08 1964-06-17 Wellcome Found Measles virus vaccine
JPS4848621A (de) * 1971-10-20 1973-07-10
JPS4868730A (de) * 1971-12-21 1973-09-19
US3915794A (en) * 1973-02-09 1975-10-28 Rit Rech Ind Therapeut Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them
JPS5648488B2 (de) * 1973-06-06 1981-11-16
JPS5341202B2 (de) * 1974-03-12 1978-11-01
US4147772A (en) * 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
AU532186B2 (en) * 1978-07-21 1983-09-22 Merck & Co., Inc. Herpes virus vaccine
PT71926B (en) * 1979-10-29 1982-03-31 Merck & Co Inc Process for preparing a liquid vaccine comprising a stabilizer
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
JPS5775929A (en) * 1980-08-28 1982-05-12 Merck & Co Inc Freeze drying method
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
HU183765B (en) * 1981-12-23 1984-05-28 Phylaxia Oltoanyagtermeloe Process for producing lyophilized vaccine against duck hepatitis
JPS6314729A (ja) 1986-06-30 1988-01-21 スミスクライン・バイオロジカルス・ソシエテ・アノニム 生ワクチン用改良安定剤、その製造法およびそれを含有するワクチン
JPS63230851A (ja) * 1987-03-20 1988-09-27 Sumitomo Metal Ind Ltd 耐食性に優れた油井管用低合金鋼
US5024836A (en) * 1987-05-04 1991-06-18 Merck & Co., Inc. Stable lyophilized live herpes virus vaccine
IE61575B1 (en) 1987-05-04 1994-11-16 Merck & Co Inc A stable lyophilized live herpes virus vaccine
JPS63307827A (ja) 1987-06-08 1988-12-15 Kitasato Inst:The 安定化された生ウイルスワクチンおよびその製造法
JP2779447B2 (ja) * 1988-03-20 1998-07-23 財団法人阪大微生物病研究会 弱毒マレック病ウイルス・ベクターを用いる組換え遺伝子作成法、及び該ウイルスの組換え体
DD299213A7 (de) * 1988-05-04 1992-04-09 Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung
FR2633518B1 (fr) 1988-06-30 1991-03-22 Merieux Inst Procede de stabilisation des vaccins et associations de vaccins a virus attenues conserves sous forme lyophilisee, et compositions obtenues
US5837261A (en) * 1990-09-25 1998-11-17 Cantab Pharmaceuticals Research Limited Viral vaccines
US5665362A (en) * 1990-09-25 1997-09-09 Cantab Pharmaceuticals Research Limited Viral vaccines
DE69132311T2 (de) 1990-09-25 2000-12-14 Cantab Pharmaceuticals Research Ltd., Cambridge Bei einer transkomplementenden zellinie erzeugter defektiver virenimpfstoff
AU673827B2 (en) 1992-03-24 1996-11-28 United Cancer Research Institute Vaccine containing live virus for therapy of viral diseases and malignancies
JPH06234659A (ja) 1992-05-05 1994-08-23 Handai Biseibutsubiyou Kenkyukai 安定化生ワクチン
CA2097019C (en) 1992-06-04 2007-07-24 Philip J. Provost Process for attenuated varicella zoster virus vaccine production
US5360736A (en) * 1992-06-04 1994-11-01 Merck & Co., Inc. Process for attenuated varicella zoster virus vaccine production
JPH08507784A (ja) 1993-03-19 1996-08-20 キャンタブ ファーマシューティカルズ リサーチ リミティド ウイルス・ワクチン
EP0728195A1 (de) * 1993-10-12 1996-08-28 Chiron Corporation Verfahren zur konservierung von rekombinanten retroviren
WO1996029096A1 (en) 1995-03-17 1996-09-26 Hisamitsu Pharmaceutical Co., Inc. Gene transfer preparation
CA2274755A1 (en) 1996-12-20 1998-07-02 Su-Pi Sheu Stabilizers for lyophilized vaccines

Also Published As

Publication number Publication date
ES2224646T3 (es) 2005-03-01
JP2002512970A (ja) 2002-05-08
WO1999055348A2 (en) 1999-11-04
ATE269712T1 (de) 2004-07-15
US6258362B1 (en) 2001-07-10
WO1999055348A3 (en) 1999-12-16
PT1071438E (pt) 2004-11-30
DE69918283T2 (de) 2005-07-21
EP1071438B1 (de) 2004-06-23
CA2329000C (en) 2010-03-23
EP1071438A2 (de) 2001-01-31
AU3718299A (en) 1999-11-16
CA2329000A1 (en) 1999-11-04
DK1071438T3 (da) 2004-10-25
GB9808922D0 (en) 1998-06-24

Similar Documents

Publication Publication Date Title
ATE269712T1 (de) Stabilisierte herpesvirusformulierung
IL124941A0 (en) Formulations of nerve growth factor suitable for lyophilization
MX9604907A (es) Vacuna de combinacion de virus para la enfermedad de newcastle.
AU4195897A (en) Chlamydial vaccines and immunogenic compositions containing an outer membrane antigen and methods of preparation thereof
BRPI0107737B1 (pt) vírus do herpes simplex 1 (hsv1), uso do hsv1, e, composição farmacêutica
NO20010576L (no) Immunologiske herpes simplex virus antigener og fremgangsmÕter for anvendelse derav
ES2124793T3 (es) Derivados de rapamicina alquilados en o y su uso, particularmente como inmunosupresores.
PT1140165E (pt) Composições de adjuvante de saponina melhoradas e métodos relacionados
AU1271799A (en) Methods for preventing and treating bacterial infections using cellulose ace tatephthalate or hydroxypropyl methylcellulose phthalate excipients
IL133220A0 (en) Stabilized antibody formulation
IL201429A (en) Weakened live virus compositions and methods to reduce disabling live viruses
NO985094D0 (no) Polymerpulver som er redispergerbart i vandige l°sninger
AU4622693A (en) Potentiation of immunogenic response
ES2035818T3 (es) Mutantes de delecion de la timidin-kinasa del virus del herpes bovino-1, vacunas contra la rinotraqueitis bovina infecciosa que los contienen y metodos para su produccion y uso.
AU7501898A (en) Live attenuated virus vaccines for equine encephalitis viruses
DE69928921D1 (de) Vormischungszusammensetzung zur bierklärung
CA2088600A1 (en) Herpes simplex virus vp16 vaccines
ES2056042T1 (es) Copolimeros solubles en agua de acetato de vinilo y acido maleamico. uso como fluidizadores o reductores de agua de alto alcance para suspensiones acuosas.
AR026637A1 (es) Virus atenuados e inocuos de la diarrea virica bovina para uso en vacas gestantes
EP1105157A4 (de) Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
WO2000012122A3 (de) Niedermolekulare fragmente der hyaluronsäure zur herstellung von impfstoffen
CA2116355A1 (en) Infectious bovine rhinotracheitis virus mutants and vaccines
TR200102168T2 (tr) BHV-1 geni silinmiş virüs aşısı.
DE69417717D1 (de) Impstoff zum Schutze von Pferden gegen Pferdeherpesvirus-Infektionen
PT858345E (pt) Uso de muteinas de citocinas do tipo selvagem como imunogenios

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee